• Publications
  • Influence
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Objective. To determine the efficacy, safety and immunogenicity of the heptavalent CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine theExpand
  • 2,129
  • 71
Efficacy of a pneumococcal conjugate vaccine against acute otitis media.
BACKGROUND Ear infections are a common cause of illness during the first two years of life. New conjugate vaccines may be able to prevent a substantial portion of cases of acute otitis media causedExpand
  • 1,426
  • 67
  • PDF
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.
We analyzed >70 recent data sets to compare the serogroups causing invasive pneumococcal disease (IPD) with those represented in conjugate vaccine formulations. Five to 8 and 10-11 serogroupsExpand
  • 825
  • 61
Adjuvants for human vaccines--current status, problems and future prospects.
Adjuvants help antigen to elicit an early, high and long-lasting immune response with less antigen, thus saving on vaccine production costs. In recent years, adjuvants received much attention becauseExpand
  • 527
  • 17
Crystal structure of an endotoxin‐neutralizing protein from the horseshoe crab, Limulus anti‐LPS factor, at 1.5 A resolution.
Lipopolysaccharide (LPS), or endotoxin, is the major mediator of septic shock, a serious complication of Gram‐negative bacterial infections in humans. Molecules that bind LPS and neutralize itsExpand
  • 231
  • 15
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children
The development of glycoconjugate vaccines for Streptococcus pneumoniae that are effective in very young children has renewed interest in identification of which among the more than 90 pneumococcalExpand
  • 221
  • 14
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
Estimates of minimum protective antibody concentrations for vaccine preventable diseases are of critical importance in assessing whether new vaccines will be as effective as those for which clinicalExpand
  • 258
  • 13
  • PDF
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.
To assess whether certain serogroups of Streptococcus pneumoniae are preferentially associated with specific disease manifestations, we analyzed all recent pneumococcal disease studies and assessedExpand
  • 348
  • 11
  • PDF
Adjuvant properties of aluminum and calcium compounds.
It is likely that aluminum compounds will continue to be used with human vaccines for many years as a result of their excellent track record of safety and adjuvanticity with a variety of antigens.Expand
  • 315
  • 8
Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS).Expand
  • 113
  • 7